Xcout IntelSign inSubscribe

Artivion, Inc.

AORTMedical DevicesKennesaw, United States

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Subscribe to see Artivion, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Artivion, Inc. at a glance

Artivion, Inc. is a medical devices company headquartered in Kennesaw, United States. It is publicly listed (AORT) with a market capitalisation of $1.4B. Xcout tracks 26 named people at Artivion, Inc., including James Patrick Mackin (Chairman, President & Chief Executive Officer).

Industry
Medical Devices
Headquarters
Kennesaw, United States
Market cap
$1.4B
Employees
1,600
Ticker
AORT

Artivion, Inc. leadership

  • James Patrick MackinChairman, President & Chief Executive Officer
  • J. Patrick MackinChairman, President, and Chief Executive Officer
  • Lance A. BerryEVice President, Chief Operating Officer, Chief Financial Officer & Treasurer
  • Lance BerryExecutive Vice President, Chief Operating Officer, and Chief Financial Officer
  • John E. DavisSenior Vice President & Chief Commercial Officer
  • Jean F. HollowaySenior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary

20 more named people on record for Artivion, Inc., with roles, board committees and tenure — see the full roster →

Artivion, Inc. competitors

A few of Artivion, Inc.'s closest competitors — see the full list of competitors and alternatives →

AtriCure, Inc.ATRC · Medical - Instruments & SuppliesMason, United States
72% matchPublic

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

Market cap$2.8B
Employees1,350
AtriCure, Inc. competitors & alternatives →
MiMedx Group, IncMDXG · Medical DevicesMarietta, United States
70% matchPublic

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

Market cap$704.9M
Employees808
MiMedx Group, Inc competitors & alternatives →
LeMaitre Vascular, Inc.LMAT · Medical DevicesBurlington, United States
69% matchPublic

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Market cap$1.9B
Employees651
LeMaitre Vascular, Inc. competitors & alternatives →
Avanos Medical, Inc.AVNS · Medical DevicesAlpharetta, United States
69% matchPublic

Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.

Market cap$1.2B
Employees2,287
Avanos Medical, Inc. competitors & alternatives →
XVIVO PERFUSION0RKL · Medical DevicesMölndal, Sweden
69% matchPublic

Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothenburg, Sweden, the company extends its operations across Sweden, the United States, the broader regions of North and South America, Europe, the Middle East, Africa, and the Asia Pacific. Their product line encompasses the XVIVO System (XPS), an integrated, off-the-shelf cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). Accompanying this is the XPS Disposable Lung Kit, supplying necessary sterile disposables and pre-packaged components. They also provide STEEN Solution, a uniquely formulated buffered extracellular solution optimized for perfusing isolated donor lungs during EVLP, and Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution for organ preservation. Additional offerings include the XVIVO Silicone Tubing Set for efficient flushing of donor lungs during procurement, as well as the XVIVO LS and XVIVO Disposable Lung Set, which together constitute a dedicated EVLP device. Furthermore, Xvivo Perfusion supplies the XVIVO Organ Chamber, a single-use sterile disposable container designed as a temporary holding unit for isolated lungs before transplantation, alongside the single-use, sterile XVIVO Lung Cannula Set.

Market cap$929.3M
Employees193
XVIVO PERFUSION competitors & alternatives →

Get Artivion, Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Artivion, Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Artivion, Inc. in Xcout Intel

  • 26 named people with titles, LinkedIn and board committees
  • 2 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →